Wall Street analysts forecast that Vitamin Shoppe, Inc (NYSE:VSI) will post $295.87 million in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Vitamin Shoppe’s earnings, with estimates ranging from $294.20 million to $296.94 million. Vitamin Shoppe reported sales of $314.89 million during the same quarter last year, which would suggest a negative year over year growth rate of 6%. The firm is expected to issue its next earnings report on Wednesday, November 1st.

On average, analysts expect that Vitamin Shoppe will report full year sales of $295.87 million for the current year, with estimates ranging from $1.18 billion to $1.25 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.19 billion per share, with estimates ranging from $1.16 billion to $1.25 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Vitamin Shoppe.

Vitamin Shoppe (NYSE:VSI) last released its quarterly earnings results on Wednesday, August 9th. The specialty retailer reported $0.23 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.39 by $0.16. Vitamin Shoppe had a positive return on equity of 8.33% and a negative net margin of 11.98%. The business had revenue of $304.84 million during the quarter, compared to analyst estimates of $314.74 million. During the same quarter last year, the firm posted $0.55 EPS. The company’s revenue was down 8.4% compared to the same quarter last year.

Several equities research analysts have recently issued reports on the company. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and issued a $6.00 price target (down from $13.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $7.00 price target (down from $14.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Barclays PLC lowered their price target on Vitamin Shoppe from $13.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 10th. TheStreet downgraded Vitamin Shoppe from a “c-” rating to a “d” rating in a research report on Wednesday, August 9th. Finally, Morgan Stanley set a $8.00 price target on Vitamin Shoppe and gave the company a “hold” rating in a research report on Thursday, August 10th. Four analysts have rated the stock with a sell rating and seven have given a hold rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $14.38.

In related news, Director John D. Bowlin bought 40,000 shares of Vitamin Shoppe stock in a transaction that occurred on Friday, August 25th. The stock was acquired at an average price of $5.50 per share, for a total transaction of $220,000.00. Following the completion of the purchase, the director now owns 56,028 shares in the company, valued at $308,154. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.07% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VSI. Point72 Asset Management L.P. bought a new stake in shares of Vitamin Shoppe in the first quarter valued at about $11,515,000. FMR LLC lifted its stake in shares of Vitamin Shoppe by 32.4% in the second quarter. FMR LLC now owns 1,254,690 shares of the specialty retailer’s stock valued at $14,617,000 after buying an additional 307,050 shares during the period. Vanguard Group Inc. lifted its stake in shares of Vitamin Shoppe by 14.8% in the first quarter. Vanguard Group Inc. now owns 2,186,549 shares of the specialty retailer’s stock valued at $44,059,000 after buying an additional 282,598 shares during the period. Olstein Capital Management L.P. lifted its stake in shares of Vitamin Shoppe by 22.9% in the first quarter. Olstein Capital Management L.P. now owns 802,133 shares of the specialty retailer’s stock valued at $16,163,000 after buying an additional 149,338 shares during the period. Finally, Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Vitamin Shoppe by 6.8% in the first quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 1,910,081 shares of the specialty retailer’s stock valued at $38,488,000 after buying an additional 122,445 shares during the period. Institutional investors and hedge funds own 96.86% of the company’s stock.

Vitamin Shoppe (NYSE:VSI) remained flat at $5.35 on Monday. The stock had a trading volume of 454,527 shares. The stock has a 50-day moving average of $8.19 and a 200 day moving average of $14.19. The stock’s market cap is $124.24 million. Vitamin Shoppe has a 12-month low of $4.95 and a 12-month high of $28.41.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Vitamin Shoppe, Inc (VSI) Will Post Quarterly Sales of $295.87 Million” was first published by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.watchlistnews.com/brokerages-anticipate-vitamin-shoppe-inc-vsi-will-post-quarterly-sales-of-295-87-million/1541552.html.

Vitamin Shoppe Company Profile

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Get a free copy of the Zacks research report on Vitamin Shoppe (VSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.